Mass-spectromètric analysis of naturally processed peptides recognized by ovarian tumor-associated CD8+ CTL

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 159-169

  Fisk, Bryan ^a   Dague, Beverly ^b   Seifert Jr , William E ^b   Kudelka, Andrzej P ^a   Wharton, J Taylor ^a   Murray, James Lee ^a   Ioannides, Constantin G ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CTL epitopes; Natural peptides; Ovarian cancer

Indexed keywords

CD8 ANTIGEN; HLA A2 ANTIGEN; PEPTIDE; TUMOR ANTIGEN;

ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031026835     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.1.159     Document Type: Article

References (33)

1. Falk K, Rotzschke O, Stevanovic S, Jung G and Rammense HG: Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296, 1991.
2. Kageyama S, Tsomides TJ, Sykulev Y and Eisen H: Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 154: 567-576, 1995.
3. Sykulev Y, Brunsmark A, Tsomides TJ, Kageyama S, Jackson M, Peterson PA and Eisen HN: High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogenic and syngeneic major histocompatibility complex class I proteins. Proc Natl Acad Sci USA 91: 11487-11491, 1994.
4. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA and Eisen HM: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by HIV type I. J Exp Med 180: 1283-1293, 1994.
5. Houghton AN: Cancer Antigens: Immune recognition of self and altered self. J Exp Med 180: 1-4, 1994.
6. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T and Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91: 6458-6462, 1994.
7. Yoshino I, Goedegeboure PS, Peoples GE, Parikh AS, DiMain JM, Lyerly HK, Gazdar AF and Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.
8. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
9. Bevan MJ: Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182: 639-641, 1995.
10. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffe E, Pardoll D and Levitsky H: Role of bone-marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965, 1994.
11. Kovacsovics-Bankowski M and Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267: 243-246, 1995.
12. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF and Slingluff CL: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719, 1994.
13. + CTL. J Exp Med 181: 363-368, 1995.
14. Ioannides CG, Fisk B, Fan D, Biddison WA, Wharton JT and O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene. Cell Immunol 151: 225-234, 1993.
15. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor specific CTL lines. J Exp Med 181: 2709-2717, 1995.
16. Slingluff Jr CL, Cox AL, Henderson RA, Hunt DF and Engelhard VH: Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol 150: 2955-2963, 1993.
17. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc Natl Acad Sci USA 88: 11276-11280, 1991.
18. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69: 989-998, 1992.
19. Wu MX, Tsomides TJ and Eisen HN: Tissue distribution of natural peptides derived from ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions. J Immunol 154: 4495-4502, 1995.
20. Kawakami Y, Eliyahu S, Sakaguchi S, Sakaguchi K, Robbins PF, Rivoltini L, Yanelli E, Appella E and Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352, 1994.
21. Emmett MR and Caprioli RM: Micro-electrospray mass spectrometry: ultra-high-sensitivity analysis of peptides and protein. J Am Soc Mass Spectrom 5: 605-613, 1994.
22. Samson I, Kerremans L, Rozenski J, Samyn B, Van Beeumen J, Van Aerschot A and Herdewijn P: Identification of a peptide inhibitor against glycosomal phosphoglycerate kinase of Trypanosoma brucei by a synthetic peptide library approach. Bioorganic Med Chem 3: 257-265, 1995.
23. Fisk B, Chesak B, Pollack Wharton JT and Ioannides CG: Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 157: 412-427, 1994.
24. + CTL. Cancer Res (In press).
25. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E and Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261-1263, 1992.
26. Christinck ER, Luscher MA, Barber BH and Williams DB: Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67-70, 1991.
27. Ioannides CG, Ioannides MG and O'Brian CA: T-cell recognition of oncogene products: a new strategy for immunotherapy. Mol Carcinogen 6: 77-81, 1992.
28. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R and Eberlein TJ: Association of HER-2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152: 2393-2400, 1994.
29. Storkus WJ, Zeh III HJ, Marurer MJ, Salter RD and Lotze MT: Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating T lymphocytes. J Immunol 151: 3719-3727, 1993.
30. Andren PE, Emmett MR and Caprioli RM: Micro-electrospray: Zeptomole/attomole per microliter sensitivity for peptide. J Am Soc Mass Spectrom 5: 867-869, 1994.
31. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM and Ehrlich R: LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 183: 499-514, 1996.
32. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M and Parmiani G: Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177: 989-998, 1993.
33. Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanik BC, Doyle CK, DeMartino GN, Bevan MJ, Forman JM and Slaughter CA: Proteolytic processing of ovalbumin and β-galactosidase by the proteasome to yield antigenic peptides. J Immunol 152: 3884, 1994.